What Is Tirzepatide?

Tirzepatide is one of the most talked-about medicines in the US right now, but the conversation around it is unusually confusing — partly because the same molecule shows up under different names, and partly because “tirzepatide” is used loosely to mean everything from a prescribed diabetes drug to a vial bought online. This page is the plain-English starting point: what the molecule actually is, how it works, why it carries two brand names, and where it stands legally in 2026. The deeper questions — what it does, what it costs, how it compares to semaglutide, how people get it — each have their own page, linked as we go.

What tirzepatide is

Tirzepatide is a synthetic peptide — a small, lab-made chain of amino acids — designed to imitate two of the hormones your gut releases after a meal. It is given as a once-weekly subcutaneous injection and is manufactured by Eli Lilly. Crucially, it is a fully FDA-approved prescription medicine, which puts it in a very different category from the “wellness” or “research” peptides (like BPC-157 or CJC-1295) that you’ll see discussed elsewhere on this site. Those are largely unapproved and obtained through gray channels; tirzepatide is a regulated pharmaceutical with a label, a manufacturer, and a defined approved use.

What makes tirzepatide genuinely novel is that it is the first approved “dual agonist” in its class. Most of the well-known drugs in this space — semaglutide, liraglutide — act on a single receptor called GLP-1. Tirzepatide acts on two: GLP-1 and a second incretin receptor called GIP (glucose-dependent insulinotropic polypeptide). That second lever is the headline scientific feature, and it’s why you’ll see tirzepatide described as a “GIP/GLP-1 dual agonist.” We’ll come back to what that means functionally below.

Note: “Peptide” here is just a description of the molecule’s chemistry, not a signal that tirzepatide belongs with unregulated research compounds. Insulin is a peptide too. The relevant distinction is regulatory status — approved drug versus unapproved compound — not the word “peptide.”

One molecule, two brands, three approved uses

This is the single most important thing to understand about tirzepatide, and the thing that confuses people most. The molecule is sold under two brand names, both made by Eli Lilly, depending on what it’s approved to treat:

• Mounjaro is tirzepatide labeled for type 2 diabetes. It was the first to market, FDA-approved in May 2022.
• Zepbound is the same molecule, labeled for two other conditions: chronic weight management (approved November 2023) and, separately, moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity (approved December 2024).

So a single active ingredient carries three FDA-approved indications across two brands. The sleep-apnea approval is a genuine first — Zepbound is the first prescription drug the FDA has cleared specifically for obstructive sleep apnea — and it matters more than a trivia point, because which brand a doctor writes, and for which condition, drives how (and whether) insurance pays. A person taking “Mounjaro for diabetes” and a person taking “Zepbound for weight loss” are on chemically identical medicine, but in two different regulatory and coverage worlds.

This is why a blanket statement like “tirzepatide works” or “tirzepatide is covered” almost always needs a follow-up question: under which brand, for which use? The coverage and prescribing mechanics of that brand split are covered on our Zepbound vs Mounjaro and how to get tirzepatide pages — this page is just here to make sure the one-molecule-two-brands fact lands first.

How it works, in plain terms

Your gut naturally releases hormones called incretins after you eat. They tell the pancreas to release insulin when blood sugar rises, they slow the rate at which the stomach empties, and they act on appetite centers in the brain to signal fullness. The two main incretins are GLP-1 and GIP.

Semaglutide and the older GLP-1 drugs mimic just the GLP-1 signal. Tirzepatide mimics both GLP-1 and GIP at once. The practical upshot, in broad strokes, is steadier blood-sugar control for people with diabetes and a strong reduction in appetite and food intake for people using it for weight — which, combined with reduced-calorie eating and more activity, is how it supports weight loss. Because it slows stomach emptying, the most common side effects are gastrointestinal (nausea, and so on), especially early on.

That’s deliberately high-level. How much it helps, how fast, and what the trial numbers actually show are not this page’s job — those belong to tirzepatide benefits, tirzepatide for weight loss, and the semaglutide vs tirzepatide comparison. The honest one-line orientation: tirzepatide posts the largest average weight-loss figures of any approved drug in its class to date, but “biggest average” is not the same as “right for everyone,” and averages hide a wide spread. The detail pages exist precisely so this explainer doesn’t oversell.

Where tirzepatide sits among the GLP-1 drugs

It helps to place tirzepatide on the map. The “GLP-1 era” of metabolic medicine runs roughly: liraglutide (daily), then semaglutide (weekly — sold as Ozempic and Rybelsus for diabetes, Wegovy for weight), and then tirzepatide (weekly — Mounjaro and Zepbound). Tirzepatide is the newest of the widely used options and the only dual agonist among them; the others are GLP-1-only.

Looking forward, even newer molecules are in development, including triple agonists such as retatrutide, which are still investigational. So tirzepatide is best understood not as the final word but as the current most-potent approved step in a fast-moving class. If you’re trying to choose between tirzepatide and semaglutide specifically, that’s a real decision with trade-offs on both sides — and it has its own dedicated page rather than a throwaway verdict here.

Its US legal and approval status in 2026

Because tirzepatide is FDA-approved, the legal picture is simpler than it is for unapproved peptides — but it changed meaningfully over 2024–2025, and a lot of outdated information is still circulating.

It is an approved drug. When prescribed as Mounjaro or Zepbound and dispensed by a normal pharmacy, tirzepatide is fully legal and routine. There’s no gray area for the brand product the way there is for research peptides.

The compounding window has closed. During the 2022–2024 supply shortage, the law temporarily allowed licensed pharmacies to compound copies of tirzepatide, which is where the cheap “$150–300 a month” telehealth offers came from. That door is now shut. The FDA removed tirzepatide from its shortage list in October 2024 and affirmed the shortage resolved that December. Enforcement discretion then ended — for state-licensed (503A) pharmacies in February 2025 and for outsourcing (503B) facilities in March 2025 — and a federal court upheld the FDA’s determination in May 2025. As a result, routine mass-compounded tirzepatide is no longer a legal pathway, and the bargain-priced compounded era is effectively over.

Note: You may still see claims online that tirzepatide is “back on the shortage list” or that compounding is widely available. As of this page’s update date, that is not accurate — the shortage was resolved and the broad compounding allowance ended. A narrow exception still exists under 503A for an individual patient with a documented medical need that the approved product can’t meet, but that is a specific clinical carve-out, not a cost-savings route, and not the same as the old shortage-era supply.

The full mechanics of that compounding question — including the safety findings that drove enforcement and the proposals tightening it further in 2026 — live on the compounded GLP-1 legal status page. Regulatory status is current as of the update date above and can change; always treat dated legal points as a snapshot.

What this page is not

Deliberately, this explainer does not give you a dose, a starting protocol, a titration schedule, or anywhere to buy anything. There are no numbers here to copy. Tirzepatide is a prescription medicine with real contraindications (including a boxed warning regarding thyroid C-cell tumors) and meaningful side effects; how it’s actually dosed is a decision a licensed prescriber makes for a specific person, after evaluating them — not something to lift from a web page. The tirzepatide dosage and tirzepatide side effects pages cover those topics in the careful, non-prescriptive way they require.

If you came here to understand what tirzepatide is, the short version is this: it’s one FDA-approved molecule, the first to hit two gut-hormone receptors at once, sold as Mounjaro for diabetes and Zepbound for weight and sleep apnea, and — as of 2026 — best accessed as the brand-name drug through a prescriber rather than the compounded versions that defined its first few years. Where you go next depends on your question, and the related links are organized for exactly that.